

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO/SP/08A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETION IF KNOWN	
				Application Number	10/020,746
				Filing Date	December 14, 2001
				First Named Inventor	R.K. Bakshi et al.
				Group Art Unit	To Be Assigned 1624
				Examiner Name	To Be Assigned Coleman
				Attorney Docket Number	19526PR
Sheet	4	of	4		

[illegible]

Examiner Signature	Brenda Coleman	Date Considered	Nov. 21, 2003
-----------------------	----------------	--------------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

SUBSTITUTE for PTO/US 08A (08-00). Information Disclosure Statement by Applicant
Patent Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COME IF KNOWN

Application Number	10/020,740
Filing Date	December 14, 2001
First Named Inventor	Bakshi, R.K. et al.
Group Art Unit	To Be Assigned 1624
Examiner Name	To Be Assigned Coleman
Attorney Docket Number	19526PR

Sheet	2	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Brenda Coleman

Date Considered

નિબંધ. ૨૧, ૨૦૨૩

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO FORM 8A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	10/020,740	
			Filing Date	December 14, 2001	
			First Named Inventor	R.K. Bakshi et al.	
			Group Art Unit	To Be Assigned 1624	
			Examiner Name	To Be Assigned Coleman	
Sheet	3	of	4	Attorney Docket Number	19526PR

OTHER NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Bakshi et al., 4-aza-3-oxo-5 α -androst-1-ene-17 β -N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5 α -reductases. J. Med. Chem. 38 (1995), pp. 3189-3192 <i>duplicate</i>
BC	AB	Andriole et al., "Treatment with Finasteride Following Radical Prostatectomy for Prostate Cancer", Urology 45(3): 491-497 (1995)
BC	AC	Tsukamoto et al., "Chemoprevention of Rat Prostate Carcinogenesis by Use of Finasteride or Casodex", 87 J. Nat'l Cancer Inst., pp. 842-843 (1995)
BC	AD	Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sept. 16-20, 1995, p.92, Abstract 48, "4-methyl-4-azasteroid 17 β (N-aryl substituted)carboxamides: Potent antiandrogenic activity with 5 α -reductase inhibition
BC	AE	Tolman et al., "4-Methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -N-aryl-carboxamide: An approach to combined androgen blockade"; in press, expected to publish in March 1996 issue of J. Steroid Biochem & Molec. Bio
BC	AF	Bologna et al., "Antiandrogens and 5- α Reductase Inhibition of the Proliferation Rate in PC3 and DU145 Human Prostatic Cancer Cell Lines", 51(6) Curr. Ther. Res., pp. 799-813 (1992)
BC	AG	Denis, Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice. Prostate 27 (1995), pp. 223-240
BC	AH	Bakshi et al., ACS Division of Medicinal Chemistry, 209th ACS Nat'l meeting Anaheim, CA, April 2-6, 1995, Abstract No. 011, "N-Phenyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamides as inhibitors of both human type 1 and type 2 5 α -reductases
BC	AI	Rasmusson et al., J. Med. Chem., Vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure-activity relationships for inhibition of 5 α -reductase and of androgen receptor binding."
BC	AJ	Liang et al., Endocrinology, Vol. 117, pp. 571-579 (1985), "Species differences in prostatic steroid 5 α -reductases of rat, dog, and human"
BC	AK	Bakshi, R.K., et al., "4-Aza-3-oxo-5 α -androst-1-ene-17 β -N-aryl-carboxamides as Dual Inhibitors of Human Type 1 and Type 2 Steroid 5 α -Reductases. Dramatic Effect of N-Aryl Substituents on Type 1 and Type 2 5 α -Reductase Inhibitory Potency.", J. Med. Chem., Vol. 38, No. 17, 1995
BC	AL	Bakshi, et al., Additions and Corrections, J. of Med. Chem., Vol. 39, No. 5, p. 1192, 1996
BC	AM	Mellin, T.N., et al., "Azasteroids as Inhibitors of Testosterone 5 α -Reductase In Mammalian Skin", J. of Steroid Biochem. and Molec. Bio., Vol. 44, No. 2, pp. 121-131, 1993
BC	AN	Rasmusson, G.H., et al., "Azasteroids as Inhibitors of Rat Prostatic 5 α -Reductase", J. of Med. Chem., Vol. 27, No. 12, pp. 1690-1701, 1984
BC	AO	Zheng, Jinhong, et al., Chem. Abs., Vol. 122, No. 25, 1995

Examiner Signature	Brenda Coleman	Date Considered	Nov. 21, 2003
--------------------	----------------	-----------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
SUBSTITUTE for PTO Form 1449A (08-00), Information Disclosure Statement by Applicant
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO			COMPLETION IF KNOWN		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number:	10/020,740 #4	
			Filing Date	December 14, 2001	
			First Named Inventor	R.K. Bakshi et al.	
			Group Art Unit	To Be Assigned 1624	
			Examiner Name	To Be Assigned Coleman	
Sheet	1	of	4	Attorney Docket Number	19526PR

Jc879 U.S. PTO
 10/020740
 10/21/01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
BC		5,302,621		Kojima et al. 514 284	04/12/1994
BC		4,191,759		Johnston et al. 424 242	03/04/1980
BC		4,377,584		Rasmusson et al. 424 258	03/22/1983
BC		5,116,983		Bhattacharya et al. 546 14	05/26/1992
BC		5,304,562		Biollaz 514 284	04/19/1994
BC		4,760,071		Rasmusson et al. 514 284	07/26/1988
BC		5,151,429		Rasmusson et al. 514 284	09/29/1992
BC		5,565,467		Batchelor et al. 514 284	10/15/1996
BC		5,693,809		Durette et al. 546 77	12/02/1997
BC		5,696,266		Humphrey et al. 546 77	12/09/1997
BC		6,121,449		Panzeri et al. 546 77	09/19/2000
BC		5,547,957		Gormley et al. 514 284	08/20/1996
BC		5,872,126		Cukierski et al. 514 284	02/16/1999
BC		5,084,574		Bhattacharya et al. 546 77	01/28/1992
BC		5,693,810		Rasmusson et al. 546 77	12/02/1997
BC		5,817,802		Humphrey et al. 540 77	10/06/1998

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
BC		PCT	WO 94/07861	Merck & Co., Inc.	04/14/1994
BC		PCT	WO 92/16213	Merck & Co., Inc.	10/01/1992
BC		EPO	0 484 094	Sankyo Company Limited	06/05/1992
BC		PCT	WO 95/07926	Glaxo Inc.	03/25/1995
** BC		EPO	0 538 192	CIBA-GEIGY AG	04/21/1993
BC		PC	WO 95/07927	Glaxo Inc.	03/23/2001
BC		PCT	WO 97/11702	Merck & Co., Inc.	04/03/1997
BC		PCT	WO 94/15602	Merck & Co., Inc.	07/21/1994
BC		PCT	WO 94/11385	Smith-Kline Beechan Corporation	05/26/1994
BC		EPO	0 004 949 A1	Merck & Co., Inc.	04/12/1979

** structures only

Examiner Signature	Brenda Coleman	Date Considered	Nov. 21, 2003
--------------------	----------------	-----------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001